Armando Sardi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Armando Sardi has a total of 335 co-authors. Here are the top co-authors by number of shared publications:
- Vadim Gushchin
Department of Surgical Oncology, Mercy Medical Center, The Institute for Cancer Care, Baltimore, USA
49 shared publications - Mary Caitlin King
Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, 227 St. Paul Place, 4th Floor Weinberg, Baltimore, MD, 21202-2001, USA
42 shared publications Carol Nieroda
41 shared publicationsVadim Gushchin
Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, 227 St. Paul Place, 4th Floor Weinberg, Baltimore, MD 21202-2001 USA
41 shared publications- Michelle Sittig
Department of Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, USA
39 shared publications - Andrei Nikiforchin
Mercy Medical Center, The Institute for Cancer Care, Department of Surgical Oncology, 227 St. Paul Place, Weinberg Building, 4th Floor, Baltimore, MD, 21202-2001, USA
32 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 65, 102118
The impact on sexual wellbeing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer treatment
- 1 June 2026
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 65, 102118
Open AccessThe impact on sexual wellbeing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer treatment
- Open Access
- 26 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5321
ASO Visual Abstract: Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- 26 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5321
Open AccessASO Visual Abstract: Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- 2 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5293-5303
Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) may lead to financial toxicity (FT), potentially impairing survivors’
- 2 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5293-5303
Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) may lead to financial toxicity (FT), potentially impairing survivors’
- 20 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5317-5318
ASO Author Reflections: Financial Toxicity as Another Dimension of Survivorship After CRS/HIPEC
- 20 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5317-5318
ASO Author Reflections: Financial Toxicity as Another Dimension of Survivorship After CRS/HIPEC
- 20 February 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (4) , 111489
Clinical characteristics and outcomes of patients with goblet cell adenocarcinoma of the appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC): A multicenter cohort study
- 20 February 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (4) , 111489
Clinical characteristics and outcomes of patients with goblet cell adenocarcinoma of the appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC): A multicenter cohort study
- 22 December 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 1974-1975
ASO Author Reflections: Decoding Conditional Risks of Recurrence in Appendix Cancer to Guide Post-Treatment Surveillance
- 22 December 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 1974-1975
ASO Author Reflections: Decoding Conditional Risks of Recurrence in Appendix Cancer to Guide Post-Treatment Surveillance
- 21 October 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (1) , 110536
Controlling perfusion temperature relates to better outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- 21 October 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (1) , 110536
Controlling perfusion temperature relates to better outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- 9 September 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (13) , 9723-9730
Recurrence Incidence and Optimal Surveillance After Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Mucinous Appendix Cancer
The optimal surveillance for mucinous appendix cancer (MAC) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) remains u
- 9 September 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (13) , 9723-9730
Recurrence Incidence and Optimal Surveillance After Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Mucinous Appendix Cancer
The optimal surveillance for mucinous appendix cancer (MAC) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) remains u
- Open Access
- 26 August 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-11
Small bowel obstruction and ovarian cancer: insights from a propensity-score matched study in patients with and without hyperthermic intraperitoneal chemotherapy after cytoreductive surgery
Small bowel obstruction (SBO) affects ~ 30% of ovarian cancer (OC) patients, leading to readmission, debilitating symptoms, and death within one year. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) effectively controls peritoneal disease. We investigated primary CRS/HIPEC’s impact on SBO and obstruction-free survival (OFS) in OC patients. A retrospective single-center cohort study of stage III/IV OC patients treated with primary optimal CRS (2014–2022) was performed. Patients who underwent upfront CRS/HIPEC vs. CRS only were matched for histology, age (> 65 years), extent of disease, FIGO stage, and surgery year, using a propensity scored full matching algorithm. CRS/HIPEC effect on OFS was determined using a weighted cox-regression model. OFS was measured from surgery to SBO/death. Overall, 102 patients were included, 29 underwent CRS/HIPEC and 73 CRS only. CRS/HIPEC had higher median number of upper abdominal procedures (4 [IQR: 3–5] vs. 1 [IQR: 0–4], p < 0.01). Postoperative major morbidity was similar (p = 0.62). After a median follow-up of 88.8 months, SBO occurred in 24.1% (n = 7) CRS/HIPEC vs. 42.0% (n = 34) CRS only (p = 0.12). Most SBOs were partial (CRS/HIPEC: 71.4%, CRS: 55.9%) and managed conservatively (CRS/HIPEC: 71.4%, CRS: 67.6%). Median OFS was 42.9 vs. 20.0 months (HR: 0.50 [95% CI 0.27–0.93], p = 0.028). One-year survival after initial SBO was 85.7% vs. 44.7%, respectively (HR: 0.79 [95% CI 0.39–1.61], p = 0.512). SBO after upfront CRS/HIPEC for OC occurred less frequently, was delayed, and had lower 1-year mortality compared to CRS alone. CRS, which includes upper abdominal exploration/surgery, coupled with HIPEC could enhance long-term peritoneal disease control in OC patients.
- 26 August 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-11
Open AccessSmall bowel obstruction and ovarian cancer: insights from a propensity-score matched study in patients with and without hyperthermic intraperitoneal chemotherapy after cytoreductive surgery
Small bowel obstruction (SBO) affects ~ 30% of ovarian cancer (OC) patients, leading to readmission, debilitating symptoms, and death within one year. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) effectively controls peritoneal disease. We investigated primary CRS/HIPEC’s impact on SBO and obstruction-free survival (OFS) in OC patients. A retrospective single-center cohort study of stage III/IV OC patients treated with primary optimal CRS (2014–2022) was performed. Patients who underwent upfront CRS/HIPEC vs. CRS only were matched for histology, age (> 65 years), extent of disease, FIGO stage, and surgery year, using a propensity scored full matching algorithm. CRS/HIPEC effect on OFS was determined using a weighted cox-regression model. OFS was measured from surgery to SBO/death. Overall, 102 patients were included, 29 underwent CRS/HIPEC and 73 CRS only. CRS/HIPEC had higher median number of upper abdominal procedures (4 [IQR: 3–5] vs. 1 [IQR: 0–4], p < 0.01). Postoperative major morbidity was similar (p = 0.62). After a median follow-up of 88.8 months, SBO occurred in 24.1% (n = 7) CRS/HIPEC vs. 42.0% (n = 34) CRS only (p = 0.12). Most SBOs were partial (CRS/HIPEC: 71.4%, CRS: 55.9%) and managed conservatively (CRS/HIPEC: 71.4%, CRS: 67.6%). Median OFS was 42.9 vs. 20.0 months (HR: 0.50 [95% CI 0.27–0.93], p = 0.028). One-year survival after initial SBO was 85.7% vs. 44.7%, respectively (HR: 0.79 [95% CI 0.39–1.61], p = 0.512). SBO after upfront CRS/HIPEC for OC occurred less frequently, was delayed, and had lower 1-year mortality compared to CRS alone. CRS, which includes upper abdominal exploration/surgery, coupled with HIPEC could enhance long-term peritoneal disease control in OC patients.